Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 4/20 | 0.45 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.45 |
| ▸ | ARG1 | P05089 | 1/20 | 0.40 |
| ▸ | ARG2 | P78540 | 1/20 | 0.40 |
| ▸ | GGT1 | P19440 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.35 |
| ▸ | BLM | P54132 | 2/20 | 0.35 |
| ▸ | THRA | P10827 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.33 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.33 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | FYN | P06241 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27699325 | 1.00 | GRM2 (0.45) | GRM2GRM3ARG1ARG2GGT1 | |
| SCHEMBL28773150 | 0.96 | GRM2 (0.49) | GRM2GRM3ARG1ARG2GGT1 | |
| SCHEMBL1814400 | 0.96 | GRM2 (0.49) | GRM2GRM3ARG1ARG2GGT1 | |
| SCHEMBL3614328 | 0.94 | GRM2 (0.51) | GRM2GRM3ARG1ARG2GGT1 | |
| SCHEMBL8957923 | 0.94 | GRM2 (0.51) | GRM2GRM3ARG1ARG2GGT1 | |
| SCHEMBL3614325 | 0.94 | GRM2 (0.51) | GRM2GRM3ARG1ARG2GGT1 | |
| SCHEMBL25660659 | 0.91 | ARG1 (0.42) | GRM2GRM3ARG1ARG2GGT1 | |
| SCHEMBL24520311 | 0.84 | ARG1 (0.38) | GRM2GRM3ARG1ARG2GGT1 | |
| SCHEMBL14931694 | 0.83 | ALOX5 (0.39) | GRM2GRM3ALOX5THRATHRB | |
| SCHEMBL27620501 | 0.82 | GGT1 (0.47) | GRM2GRM3ARG1ARG2GGT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110124705-A1 | PRODRUGS OF ALPHA-2-DELTA LIGANDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2011-05-26 | — | — | US | claimed |
| CN-101166524-B | Amino acid derivatives | PFIZER | 2010-12-22 | — | — | CN | claimed |
| CN-101166524-A | Amino acid derivatives | PFIZER (GB) | 2008-04-23 | — | — | CN | claimed |
| EP-1879567-A1 | AMINO ACID DERIVATIVES | Pfizer Limited (GB) | 2008-01-23 | — | — | EP | claimed |
| US-20060247291-A1 | Amino acid derivatives | PFIZER, INC. | 2006-11-02 | — | — | US | claimed |
| WO-2006114707-A1 | AMINO ACID DERIVATIVES | PFIZER LIMITED (GB) | 2006-11-02 | — | — | WO | claimed |
| US-20110130454-A1 | PRODRUGS OF GAMMA-AMINO ACID, ALPHA-2-DELTA LIGANDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2011-06-02 | — | — | US | disclosed |
| US-20110124705-A1 | PRODRUGS OF ALPHA-2-DELTA LIGANDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2011-05-26 | — | — | US | disclosed |
| CN-101166524-B | Amino acid derivatives | PFIZER | 2010-12-22 | — | — | CN | disclosed |
| US-7612226-B2 | Amino acid derivatives | PFIZER INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-7612226-B2 | Amino acid derivatives | PFIZER INC. (US) | 2009-11-03 | — | — | US | disclosed |
| CN-101166524-A | Amino acid derivatives | PFIZER (GB) | 2008-04-23 | — | — | CN | disclosed |
| EP-1879567-A1 | AMINO ACID DERIVATIVES | Pfizer Limited (GB) | 2008-01-23 | — | — | EP | disclosed |
| US-20060247291-A1 | Amino acid derivatives | PFIZER, INC. | 2006-11-02 | — | — | US | disclosed |
| WO-2006114707-A1 | AMINO ACID DERIVATIVES | PFIZER LIMITED (GB) | 2006-11-02 | — | — | WO | disclosed |
| WO-2006114707-A1 | AMINO ACID DERIVATIVES | PFIZER LIMITED (GB) | 2006-11-02 | — | — | WO | disclosed |
| WO-2006092692-A1 | USE OF COMBINATIONS OF PDE7 INHIBITORS AND ALPHA-2-DELTY LIGANDS FOR THE TREATMENT OF NEUROPATHIC PAIN | PFIZER LIMITED (GB) | 2006-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247291-A1 | Amino acid derivatives | OPRL1, BCAT2, BCAT1 | GRM2 411/4885GRM3 235/4885ARG1 18/4885 |
| US-20110130454-A1 | PRODRUGS OF GAMMA-AMINO ACID, ALPHA-2-DELTA LIGANDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | CHRND, CHRNE, OPRD1 | GRM2 297/4885GRM3 728/4885ARG1 655/4885 |
| US-20110124705-A1 | PRODRUGS OF ALPHA-2-DELTA LIGANDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | CHRND, CHRNE, CHRNG | GRM2 664/4885GRM3 1671/4885ARG1 2293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.